Servier Expands Portfolio with $2.5B Rare Cancer Acquisition
- 7 days ago
- 2 min read
In a major advancement for pediatric oncology, the independent French pharmaceutical group Servier announced a definitive agreement today to acquire Day One Biopharmaceuticals. The all-cash transaction, priced at $21.50 per share, represents a total equity value of approximately $2.5 billion and is expected to close in the second quarter of 2026.
The centerpiece of this high-profile buyout is Day One's targeted therapy, Ojemda (tovorafenib). Approved by the FDA in April 2024, Ojemda is designed to treat patients aged six months and older who are battling relapsed or refractory pediatric low-grade glioma (pLGG)—the most common type of childhood brain tumor.
This strategic move significantly deepens Servier's footprint in the rare oncology sector. Ojemda will naturally complement Voranigo, Servier’s existing targeted therapy for IDH-mutant glioma, which the company secured through its $2 billion acquisition of Agios Pharmaceuticals in 2021. The deal also gives Servier access to Day One's broader early-to-late-stage pipeline, which includes treatments for adult and pediatric solid tumors.
Servier, uniquely governed by a non-profit foundation, has consistently emphasized a patient-centric approach. David Lee, CEO of Servier’s U.S. arm, noted that this unique governance model empowers the company to "invest in diseases that other people would not be able to make a business case for," committing to urgent scientific needs over short-term thinking.
The acquisition is perfectly aligned with Servier's aggressive 2030 ambition to reach 10 billion euros ($11.5 billion) in annual sales. Having already seen its oncology business grow by 55% in the 2024-2025 fiscal year, Servier's latest investment ensures the company continues to accelerate innovation for communities facing severe, unmet medical needs.
🔖 Sources
Keywords: Rare Cancer Acquisition
Rare Cancer Acquisition
Comments